
    
      Patients with pulmonary hypertension (PH) complicating pulmonary fibrosis are at increased
      risk of death. There are no therapies proven to be effective in this population, targeting
      the pulmonary hypertension. The purpose of this study is to evaluate parenteral treprostinil
      in an open-label fashion in patients with pulmonary fibrosis and an advanced PH phenotype.
    
  